Drug profile · INN
selumetinib sulfate
KOSELUGO
selumetinib sulfate (KOSELUGO) is a dual specificity mitogen-activated protein kinase kinase; mek1/2 inhibitor. Route of administration: oral. Current US regulatory status: approved.
Drug details — selumetinib sulfate
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 1
- Data quality
- 0.84
Quick answer
selumetinib sulfate (KOSELUGO) is a dual specificity mitogen-activated protein kinase kinase; mek1/2 inhibitor. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Dual specificity mitogen-activated protein kinase kinase; MEK1/2 inhibitor
Primary target: Dual specificity mitogen-activated protein kinase kinase 1
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is selumetinib sulfate?
selumetinib sulfate (KOSELUGO) is a dual specificity mitogen-activated protein kinase kinase; mek1/2 inhibitor. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for selumetinib sulfate?
KOSELUGO is a marketed brand name for selumetinib sulfate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of selumetinib sulfate?
selumetinib sulfate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.